Health Catalyst reported second quarter 2026 results and announced the completion of its Vitalware divestiture and full repayment of credit facility debt. Total revenue was $70.5 million, a 13% decrease from $80.7 million in the prior year period, while adjusted EBITDA was $9.9 million compared to $9.3 million a year earlier. The company sold Vitalware to Med-Metrix for $147 million in total cash consideration, using the proceeds plus cash on hand to retire approximately $160 million in credit facility debt, eliminating an estimated $19 million in annual GAAP interest expense. Full year 2026 revenue guidance was updated to $246 million to $249 million, reflecting the removal of five months of Vitalware revenue, and adjusted EBITDA guidance was set at $18 million to $18.5 million. Management also noted $12.5 million of notified annual recurring revenue down-sell and churn related to the DOS-to-Ignite platform migration, with approximately $52 million in additional ARR identified as at risk.
Health Catalyst IncCompleted Vitalware divestiture and repaid debt, reducing interest expense and improving balance sheet.
